Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Ovarian Neoplasms

Adenocarcinoma Of Esophagus, Barrett Esophagus

Carcinoma, Hepatocellular

Biliary Tract Neoplasms

Adenocarcinoma of Lung, Brain Neoplasms

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Endometrial Neoplasms

Triple Negative Breast Neoplasms

Ovarian Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Carcinoma, Hepatocellular

Colonic Neoplasms, Rectal Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Neoplasms

Carcinoma, Hepatocellular

Colorectal Neoplasms

Ovarian Neoplasms

Rectal Neoplasms

HER2-low Breast Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

Colorectal Cancer Metastatic

Brain Neoplasms, Glioma, Radiation Injuries

Carcinoma, Hepatocellular, Cholangiocarcinoma

Ependymoma, Medulloblastoma, Recurrence

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Hepatocellular

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

Glioblastoma, Recurrence

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

Malignant Ascites

Colorectal Neoplasms

Ovarian Neoplasms

pMMR/MSS Locally Advanced Rectal Cancer

Triple Negative Breast Neoplasms

Rectal Neoplasms

Hepatecellular Carcinoma

Colorectal Neoplasms

Neuroblastoma

Glioblastoma

Carcinoma, Hepatocellular

Colorectal Neoplasms

Colorectal Cancer Metastatic

Ovarian Neoplasms

Clinical Trials

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

MOMENTUM-1

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

NIRVANA-1

SLURP

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases

IMMUNOLIFE2

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

EndoMAP

MINUTE

BCTOP-T-M01

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

SCOTI

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

TERTIO

TRIBE-C

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

FOBEAR

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis

BRAINS

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

MEMMAT

PRELUDE

SBRT With Atezo/Bev for HCC

CHIMERA

Phenix

Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy

CAPRI-3 GOIM

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

BEACON2

PRIDE

β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

BASKETⅢ

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

Autophagy Maintenance (AUTOMAIN)